These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23844194)

  • 1. Analysis of conformational determinants underlying HSP90-kinase interaction.
    Kancha RK; Bartosch N; Duyster J
    PLoS One; 2013; 8(7):e68394. PubMed ID: 23844194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants.
    Prince TL; Kijima T; Tatokoro M; Lee S; Tsutsumi S; Yim K; Rivas C; Alarcon S; Schwartz H; Khamit-Kush K; Scroggins BT; Beebe K; Trepel JB; Neckers L
    PLoS One; 2015; 10(10):e0141786. PubMed ID: 26517842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex.
    Xu W; Yuan X; Xiang Z; Mimnaugh E; Marcu M; Neckers L
    Nat Struct Mol Biol; 2005 Feb; 12(2):120-6. PubMed ID: 15643424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome.
    An WG; Schulte TW; Neckers LM
    Cell Growth Differ; 2000 Jul; 11(7):355-60. PubMed ID: 10939589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.
    Wu LX; Xu JH; Zhang KZ; Lin Q; Huang XW; Wen CX; Chen YZ
    Leukemia; 2008 Jul; 22(7):1402-9. PubMed ID: 18418407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex.
    Shiotsu Y; Neckers LM; Wortman I; An WG; Schulte TW; Soga S; Murakata C; Tamaoki T; Akinaga S
    Blood; 2000 Sep; 96(6):2284-91. PubMed ID: 10979978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hsp90 N- and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells.
    Chen C; Zhuang Y; Chen X; Chen X; Li D; Fan Y; Xu J; Chen Y; Wu L
    Oncotarget; 2017 Feb; 8(6):10025-10036. PubMed ID: 28036294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells.
    Castagnola P; Bellese G; Birocchi F; Gagliani MC; Tacchetti C; Cortese K
    Oncotarget; 2016 Dec; 7(51):85411-85429. PubMed ID: 27863425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
    Kamal A; Thao L; Sensintaffar J; Zhang L; Boehm MF; Fritz LC; Burrows FJ
    Nature; 2003 Sep; 425(6956):407-10. PubMed ID: 14508491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.
    Rao R; Fiskus W; Yang Y; Lee P; Joshi R; Fernandez P; Mandawat A; Atadja P; Bradner JE; Bhalla K
    Blood; 2008 Sep; 112(5):1886-93. PubMed ID: 18591380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
    George P; Bali P; Annavarapu S; Scuto A; Fiskus W; Guo F; Sigua C; Sondarva G; Moscinski L; Atadja P; Bhalla K
    Blood; 2005 Feb; 105(4):1768-76. PubMed ID: 15514006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The conformation-specific Hsp90 inhibition interferes with the oncogenic RAF kinase adaptation and triggers premature cellular senescence, hence, acts as a tumor suppressor mechanism.
    Kanugovi Vijayavittal A; Amere Subbarao S
    Biochim Biophys Acta Mol Cell Res; 2021 Mar; 1868(3):118943. PubMed ID: 33359710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heat shock protein 90 stabilization of ErbB2 expression is disrupted by ATP depletion in myocytes.
    Peng X; Guo X; Borkan SC; Bharti A; Kuramochi Y; Calderwood S; Sawyer DB
    J Biol Chem; 2005 Apr; 280(13):13148-52. PubMed ID: 15671027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors.
    Beebe K; Mollapour M; Scroggins B; Prodromou C; Xu W; Tokita M; Taldone T; Pullen L; Zierer BK; Lee MJ; Trepel J; Buchner J; Bolon D; Chiosis G; Neckers L
    Oncotarget; 2013 Jul; 4(7):1065-74. PubMed ID: 23867252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ; Margaritis LH; Voutsinas GE
    Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells.
    Samant RS; Clarke PA; Workman P
    Proc Natl Acad Sci U S A; 2014 May; 111(18):6834-9. PubMed ID: 24760825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
    Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K
    Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
    Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
    Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
    Bonvini P; Gastaldi T; Falini B; Rosolen A
    Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation.
    Jiao Y; Ou W; Meng F; Zhou H; Wang A
    Mol Cancer; 2011 Sep; 10():125. PubMed ID: 21962244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.